New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
10:07 EDTFOR, WPRT, OMCL, PKOH, BRO, SKS, EBAY, STRZA, MMC, CHMT, SRPT, RHT, BIOS, AMZN, BMR, ACT, BXP, AON, ACNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accenture (ACN) initiated with an Overweight at Evercore... Actavis (ACT) initiated with an Overweight at Morgan Stanley... Amazon.com (AMZN) initiated with a Buy at ISI Group... Aon Corp. (AON) initiated with a Market Perform at Wells Fargo... BioMed Realty (BMR) initiated with a Neutral at Goldman... BioScrip (BIOS) initiated with a Buy at SunTrust... Boston Properties (BXP) initiated with an Overweight at Evercore... Brown & Brown (BRO) initiated with a Market Perform at Wells Fargo... Forestar Group (FOR) initiated with a Buy at DA Davidson... Marsh & McLennan (MMC) initiated with an Outperform at Wells Fargo... Park-Ohio (PKOH) initiated with an Outperform at Imperial Capital... Red Hat (RHT) initiated with an Outperform at Northland Securities... Starz (STRZA) initiated with a Sell at Stifel Nicolaus... Starz (STRZA) initiated with an Underweight at Evercore... Omnicell (OMCL) initiated with a Buy at Benchmark Co... Sarepta (SRPT) initiated with an Outperform at Cowen... eBay (EBAY) initiated with a Positive at Susquehanna... Westport Innovations (WPRT) initiated with a Market Perform at Raymond James... Chemtura (CHMT) initiated with a Buy at Sidoti... Saks (SKS) initiated with a Buy at Maxim.
News For ACN;ACT;AMZN;AON;BMR;BIOS;BXP;BRO;FOR;MMC;PKOH;RHT;STRZA;OMCL;SRPT;EBAY;WPRT;CHMT;SKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
August 21, 2015
08:32 EDTSRPTSarepta says FDA grants rare pediatric disease designation for Eteplirsen
Subscribe for More Information
August 20, 2015
18:59 EDTAMZNGoogle, Amazon, private equity compete for Indian data center unit, ET says
Subscribe for More Information
18:20 EDTAMZNAuthors Group urges DOJ probe of Amazon.com, WSJ reports
Authors United group is urging the DOJ to launch an investigation into Amazon.com, claiming the company has "unprecedented power" over the book publishing market, the Wall Street Journal reports. Reference Link
16:33 EDTAMZNAmazon.com to open fifth Texas fulfillment center in San Marcos
Subscribe for More Information
13:18 EDTAMZNAmazon.com falls, levels to watch
The shares are down 2.8% at time of writing to $517.99. The last established support level before the large bullish gap from last earnings is at $513.06. If that level is taken out on the downside, a gam fill will begin. And the chart will be left with a blow-off top formation. Resistance is at $522.62.
12:56 EDTAMZNSmall drones bringing air traffic problems in U.S., Washington Post reports
Subscribe for More Information
11:49 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
08:33 EDTOMCLOmnicell appoints Peter Kuipers as CFO
Omnicell appointed Peter Kuipers as Executive VP and CFO. Prior to joining Omnicell, Kuipers served as CFO at Quantcast Corporation. Current CFO Rob Seim now completes the transition to his new role as Executive VP, International and Global Quality & Manufacturing.
06:05 EDTAMZNAmazon Web Services to open data support center in London, Financial Times says
Subscribe for More Information
05:56 EDTAMZNGoogle Express to shut down two California delivery hubs, Re/code says
Subscribe for More Information
August 19, 2015
16:08 EDTACNLeidos awarded $4.3B DoD contract
Leidos (LDOS) was awarded a prime contract by the Department of Defense, or DoD, to provide an off-the-shelf electronic health record solution, integration activities and deployment across the Military Health System. The contract, known as the Defense Healthcare Management System Modernization, or DHMSM, program, is an initiative designed to modernize the military's healthcare system in a meaningful way, enabling patients and clinicians to capture and share health data that can improve the continuity and quality of care for 9.6M active military, their families, and their beneficiaries. As the prime contractor, Leidos established a team of proven innovators and industry leaders to form the Leidos Partnership for Defense Health. Cerner (CERN), Accenture Federal Services (ACN) and Henry Schein (HSIC) form the core team, complemented with a broad range of large and small business teammates, vendors and suppliers who bring proven experience and expertise specific to both the commercial and DoD healthcare markets.
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
09:16 EDTEBAYNew Relic, Magneto announce expansion of partnership
Subscribe for More Information
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
07:42 EDTAMZNPhoenix Amazon warehouse evacuated due to chemical leak, ABC15 says
Subscribe for More Information
August 18, 2015
18:06 EDTAMZNAmazon tests 'Flex' package pickup service, GeekWire says
Subscribe for More Information
16:00 EDTAMZNAmazon workplace policies making U.K. staff physically ill, Guardian says
Subscribe for More Information
10:39 EDTCHMTChemtura management to meet with Longbow
Subscribe for More Information
06:39 EDTAMZNUSPS boosts same-day delivery to compete with FedEx, UPS, Amazon, WSJ says
Subscribe for More Information
06:08 EDTEBAYeBay expected to announce sale of some of Snapdeal stake, Re/code reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use